Last 12 months
Inside the activity.
0 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 0 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 15, 2022 Filed Feb 17, 2022 16:15 UTC |
Ni FangSEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001513 · form4-02172022_010232.xml · derivative · entry 1 Ni Fang · CIK 0001895910 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 16:16 UTC |
Buck ElizabethCHIEF SCIENTIFIC OFFICER
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001514 · form4-02172022_010238.xml · derivative · entry 1 Buck Elizabeth · CIK 0001880385 · CHIEF SCIENTIFIC OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:21 UTC |
Hatzis-Schoch BrentSEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001518 · form4-02172022_010257.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 15, 2022 Filed Feb 17, 2022 21:19 UTC |
Epstein David M.Director · SEE REMARKS
|
GrantStock Option (Right to Buy) · Derivative | 300,000 | $0.00 Strike: $3.79 | $0.00 |
DisclosureSEC source: 0001415889-22-001517 · form4-02172022_010237.xml · derivative · entry 1 Epstein David M. · CIK 0001488668 · Director · SEE REMARKS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 300,000 Underlying: Common Stock · 300,000 shares Expires 2032-02-14 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 15, 2023, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 21:50 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 2,472 | $5.31 | $13,126.32 |
DisclosureSEC source: 0001209191-21-070311 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,359 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 16, 2021. Read SEC document |
| December 17, 2021 Filed Dec 17, 2021 21:12 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 3,296 | $5.31 | $17,501.76 |
DisclosureSEC source: 0001415889-21-006070 · form4-12172021_011225.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,602 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on December 16, 2021. Read SEC document |
| September 17, 2021 Filed Sep 23, 2021 21:43 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 1,326 | $9.90 | $13,127.40 |
DisclosureSEC source: 0001209191-21-057470 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,887 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 16, 2021. Read SEC document |
| September 17, 2021 Filed Sep 23, 2021 21:33 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 1,869 | $9.90 | $18,503.10 |
DisclosureSEC source: 0001415889-21-004540 · form4-09232021_020923.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,306 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on September 16, 2021. Read SEC document |
| August 09, 2021 Filed Aug 11, 2021 20:58 UTC |
Velleca Mark A.Director
|
GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $9.85 | $0.00 |
DisclosureSEC source: 0001415889-21-003856 · form4-08112021_010801.xml · derivative · entry 1 Velleca Mark A. · CIK 0001706847 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2031-08-08 F1 · derivative.exercise_date: This option shall vest and become exercisable in thirty-six (36) equal monthly installments following the Grant Date. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 23:18 UTC |
Behbahani AliDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001209191-21-042549 · doc4.xml · derivative · entry 3 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F4 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 23:18 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 1,014 | $12.95 | $13,131.30 |
DisclosureSEC source: 0001209191-21-042549 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,561 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 17, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:16 UTC |
Shah Rajeev M.Director
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084246 · tm2120371-3_4seq1.xml · derivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. F2 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the shares underlying the option for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received as compensation from the Issuer, which will offset advisory fees owed by the Fund and the Nexus Fund to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the common stock underlying the option. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:15 UTC |
Menzel Garry EDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084245 · tm2120371-5_4seq1.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:14 UTC |
Mayweg AlexanderDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084244 · tm2120371-7_4seq1.xml · derivative · entry 1 Mayweg Alexander · CIK 0001786260 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:14 UTC |
Kulkarni SamarthDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084243 · tm2120371-4_4seq1.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:13 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084242 · tm2120371-6_4seq1.xml · derivative · entry 2 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F3 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:13 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 1,255 | $12.95 | $16,252.25 |
DisclosureSEC source: 0001104659-21-084242 · tm2120371-6_4seq1.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,437 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on June 17, 2021. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:13 UTC |
Dhingra KapilDirector
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084241 · tm2120371-2_4seq1.xml · derivative · entry 1 Dhingra Kapil · CIK 0001456849 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 22:12 UTC |
Bolzon Bradley J PhDDirector · 10% owner
|
GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $12.55 | $0.00 |
DisclosureSEC source: 0001104659-21-084239 · tm2120371-1_4seq1.xml · derivative · entry 1 Bolzon Bradley J PhD · CIK 0001354345 · Director · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-17 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 18, 2022 or (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| May 20, 2021 Filed May 21, 2021 21:52 UTC |
Shah Rajeev M.Director
|
OtherCommon Stock | 443 | $24.01 | $10,636.43 |
DisclosureSEC source: 0001104659-21-070583 · tm2116949-1_4seq1.xml · nonDerivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: On March 18, 2021, 443 shares were issued to the Reporting Person in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy in lieu of cash compensation for the Reporting Person's annual services as a non-employee director of the Issuer. The Reporting Person's election to receive shares in lieu of cash compensation was inadvertent and the Reporting Person is transferring the shares to the Issuer in exchange for the cash compensation that would otherwise have been paid to the Reporting Person had the election not been made. The transfer of the shares back to the Issuer was approved pursuant to Rule 16b-3 of the Securities Exchange Act of 1934, as amended. F2 · price: The price reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 18, 2021, the date the shares were issued to the Reporting Person. F3 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person is obligated to turn over to the Adviser any compensation (including net cash or stock, as applicable) from the Issuer, as an offset to advisory fees owed to the Adviser by RA Capital Healthcare Fund, L.P. (the "Fund") and RA Capital Nexus Fund, L.P. (the "Nexus Fund"). The Reporting Person therefore disclaims beneficial ownership of the common stock.. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC |
Hatzis-Schoch BrentSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · derivative · entry 5 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 160,474 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC |
Hatzis-Schoch BrentSee Remarks
|
SaleCommon Stock | 351 | $28.20 | $9,899.74 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 4 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F4 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $28.12 to $28.24, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC |
Hatzis-Schoch BrentSee Remarks
|
SaleCommon Stock | 2,566 | $27.90 | $71,596.02 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,751 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $27.095 to $28.06, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC |
Hatzis-Schoch BrentSee Remarks
|
SaleCommon Stock | 1,161 | $26.11 | $30,309.07 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,317 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.81 to $26.67, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 12, 2021 Filed May 13, 2021 20:53 UTC |
Hatzis-Schoch BrentSee Remarks
|
Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0001104659-21-065995 · tm2116337-1_4seq1.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:31 UTC |
Roberts Christopher D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-21-018358 · doc4.xml · derivative · entry 3 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 163,609 Underlying: Common Stock · 2,500 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:31 UTC |
Roberts Christopher D.Chief Scientific Officer
|
SaleCommon Stock | 2,500 | $26.64 | $66,602.25 |
DisclosureSEC source: 0000899243-21-018358 · doc4.xml · nonDerivative · entry 2 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.32 to $27.18, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| May 03, 2021 Filed May 5, 2021 20:31 UTC |
Roberts Christopher D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,500 | $10.86 | $27,150.00 |
DisclosureSEC source: 0000899243-21-018358 · doc4.xml · nonDerivative · entry 1 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 20, 2021 Filed Apr 24, 2021 01:14 UTC |
Menzel Garry EDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,921 | $0.00 Strike: $24.33 | $0.00 |
DisclosureSEC source: 0001104659-21-054611 · tm2113912-2_4seq1.xml · derivative · entry 1 Menzel Garry E · CIK 0001556064 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,921 Underlying: Common Stock · 14,921 shares Expires 2031-04-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2021 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 20, 2021 Filed Apr 24, 2021 01:14 UTC |
Kulkarni SamarthDirector
|
GrantStock Option (Right to Buy) · Derivative | 14,921 | $0.00 Strike: $24.33 | $0.00 |
DisclosureSEC source: 0001104659-21-054610 · tm2113912-1_4seq1.xml · derivative · entry 1 Kulkarni Samarth · CIK 0001682019 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,921 Underlying: Common Stock · 14,921 shares Expires 2031-04-19 F1 · derivative.exercise_date: This option shall vest and become exercisable in full upon the earlier to occur of (i) June 12, 2021 and (ii) the next annual meeting of the Issuer's stockholders. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 00:45 UTC |
Hatzis-Schoch BrentSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 179,915 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-21-015666 · doc4.xml · derivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 164,552 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 00:45 UTC |
Hatzis-Schoch BrentSee Remarks
|
SaleCommon Stock | 4,078 | $25.00 | $101,950.00 |
DisclosureSEC source: 0000899243-21-015666 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. Read SEC document |
| April 12, 2021 Filed Apr 14, 2021 00:45 UTC |
Hatzis-Schoch BrentSee Remarks
|
Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-21-015666 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC |
Roberts Christopher D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-21-015309 · doc4.xml · derivative · entry 3 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 166,109 Underlying: Common Stock · 2,500 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC |
Roberts Christopher D.Chief Scientific Officer
|
SaleCommon Stock | 2,500 | $25.54 | $63,847.50 |
DisclosureSEC source: 0000899243-21-015309 · doc4.xml · nonDerivative · entry 2 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.165 to $26.085, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| April 05, 2021 Filed Apr 7, 2021 21:17 UTC |
Roberts Christopher D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,500 | $10.86 | $27,150.00 |
DisclosureSEC source: 0000899243-21-015309 · doc4.xml · nonDerivative · entry 1 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:34 UTC |
Shah Rajeev M.Director
|
OtherCommon Stock | 353,814 | $24.26 | $8,583,527.64 |
DisclosureSEC source: 0001104659-21-046615 · tm2112163-10_4seq1.xml · nonDerivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 2,277,978 F1 · kind: On April 1, 2021, RA Capital Healthcare Fund, L.P. (the "Fund") acquired the reported shares as part of a reorganization of the assets of a separately managed account. F1 · price: On April 1, 2021, RA Capital Healthcare Fund, L.P. (the "Fund") acquired the reported shares as part of a reorganization of the assets of a separately managed account. F2 · balance_after: Held directly by the Fund. F1 · ownership.nature: On April 1, 2021, RA Capital Healthcare Fund, L.P. (the "Fund") acquired the reported shares as part of a reorganization of the assets of a separately managed account. F4 · ownership.nature: RA Capital Management, L.P. (the "Adviser") is the investment manager for the Fund and the Nexus Fund. The general partner of the Adviser is RA Capital Management GP, LLC (the "Adviser GP"), of which Dr. Peter Kolchinsky and Mr. Rajeev Shah are the managing members. The Adviser, the Adviser GP, Dr. Kolchinsky and Mr. Shah disclaim beneficial ownership of any of the reported securities, except to the extent of their pecuniary interest therein. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 00:33 UTC |
Behbahani AliDirector
|
GrantCommon Stock | 547 | $24.01 | $13,133.47 |
DisclosureSEC source: 0001209191-21-022462 · doc4.xml · nonDerivative · entry 1 Behbahani Ali · CIK 0001613867 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 547 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price of reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 18, 2021. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 00:25 UTC |
Shah Rajeev M.Director
|
GrantCommon Stock | 443 | $24.01 | $10,636.43 |
DisclosureSEC source: 0000899243-21-012956 · doc4.xml · nonDerivative · entry 1 Shah Rajeev M. · CIK 0001619841 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 443 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price of reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 18, 2021. F3 · ownership.direct: Under the Reporting Person's arrangement with RA Capital Management, L.P. (the "Adviser"), the Reporting Person holds the shares for the benefit of the RA Capital Healthcare Fund, L.P. (the "Fund"), RA Capital Nexus Fund, L.P. (the "Nexus Fund") and a separately managed account (the "Account"). The Reporting Person is obligated to turn over to the Adviser any net cash or stock received as compensation from the Issuer, which will offset advisory fees owed by the Fund, the Nexus Fund and the Account to the Adviser. The Reporting Person therefore disclaims beneficial ownership of the common stock. Read SEC document |
| March 18, 2021 Filed Mar 23, 2021 00:19 UTC |
INGRAM ROBERT ALEXANDERDirector
|
GrantCommon Stock | 677 | $24.01 | $16,254.77 |
DisclosureSEC source: 0000899243-21-012953 · doc4.xml · nonDerivative · entry 1 INGRAM ROBERT ALEXANDER · CIK 0001219890 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,182 F1 · kind: These shares were issued in accordance with the Issuer's Amended and Restated Non-Employee Director Compensation Policy, pursuant to which the Reporting Person elected to receive shares of the Issuer's common stock in lieu of cash compensation for annual services as a non-employee director of the Issuer. F2 · price: The price of reported in Column 4 is based upon the closing market price of the Issuer's common stock on March 18, 2021. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:56 UTC |
Hatzis-Schoch BrentSee Remarks
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 4,078 | $0.00 Strike: $3.20 | $0.00 |
DisclosureSEC source: 0000899243-21-011958 · doc4.xml · derivative · entry 3 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,630 Underlying: Common Stock · 4,078 shares Expires 2029-06-11 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on May 22, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:56 UTC |
Hatzis-Schoch BrentSee Remarks
|
SaleCommon Stock | 4,078 | $26.36 | $107,493.23 |
DisclosureSEC source: 0000899243-21-011958 · doc4.xml · nonDerivative · entry 2 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,400 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 12, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.8375 to $26.65, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 12, 2021 Filed Mar 16, 2021 20:56 UTC |
Hatzis-Schoch BrentSee Remarks
|
Exercise / conversionCommon Stock | 4,078 | $3.20 | $13,049.60 |
DisclosureSEC source: 0000899243-21-011958 · doc4.xml · nonDerivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,478 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 22:52 UTC |
Roberts Christopher D.Chief Scientific Officer
|
Exercise / conversionStock Option (Right to Buy) · Derivative | 2,500 | $0.00 Strike: $10.86 | $0.00 |
DisclosureSEC source: 0000899243-21-009904 · doc4.xml · derivative · entry 4 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 168,609 Underlying: Common Stock · 2,500 shares Expires 2029-09-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: 25% of the shares subject to this option vested and became exercisable on September 3, 2020, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 22:52 UTC |
Roberts Christopher D.Chief Scientific Officer
|
SaleCommon Stock | 884 | $26.57 | $23,483.55 |
DisclosureSEC source: 0000899243-21-009904 · doc4.xml · nonDerivative · entry 3 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $26.50 to $26.61, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 22:52 UTC |
Roberts Christopher D.Chief Scientific Officer
|
SaleCommon Stock | 1,616 | $25.85 | $41,778.29 |
DisclosureSEC source: 0000899243-21-009904 · doc4.xml · nonDerivative · entry 2 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,084 F1 · kind: Shares sold pursuant to a pre-established 10b5-1 trading plan effective as of June 2, 2020. F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $25.355 to $26.14, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. Read SEC document |
| March 03, 2021 Filed Mar 4, 2021 22:52 UTC |
Roberts Christopher D.Chief Scientific Officer
|
Exercise / conversionCommon Stock | 2,500 | $10.86 | $27,150.00 |
DisclosureSEC source: 0000899243-21-009904 · doc4.xml · nonDerivative · entry 1 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,700 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:06 UTC |
Hatzis-Schoch BrentSee Remarks
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007450 · doc4.xml · derivative · entry 1 Hatzis-Schoch Brent · CIK 0001637054 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 00:01 UTC |
Roberts Christopher D.Chief Scientific Officer
|
GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007445 · doc4.xml · derivative · entry 1 Roberts Christopher D. · CIK 0001788368 · Chief Scientific Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
| February 17, 2021 Filed Feb 19, 2021 23:55 UTC |
HUMPHREY RACHELChief Medical Officer
|
GrantStock Option (Right to Buy) · Derivative | 60,000 | $0.00 Strike: $28.69 | $0.00 |
DisclosureSEC source: 0000899243-21-007440 · doc4.xml · derivative · entry 1 HUMPHREY RACHEL · CIK 0001579781 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 60,000 Underlying: Common Stock · 60,000 shares Expires 2031-02-16 F1 · derivative.exercise_date: 25% of the shares subject to this option shall vest and become exercisable on February 17, 2022, with the remainder vesting in 36 equal monthly installments thereafter. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.